These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 4714098

  • 1. An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy.
    Mones RJ.
    J Neurol Neurosurg Psychiatry; 1973 Jun; 36(3):362-7. PubMed ID: 4714098
    [Abstract] [Full Text] [Related]

  • 2. Interactions of L-dopa and amantadine in patients with Parkinsonism.
    Cox B, Danta G, Schnieden H, Yuill GM.
    J Neurol Neurosurg Psychiatry; 1973 Jun; 36(3):354-61. PubMed ID: 4714097
    [Abstract] [Full Text] [Related]

  • 3. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W, Linauer W, Mentasti M, Riederer P.
    Wien Med Wochenschr; 1974 Jun 01; 124(22):340-4. PubMed ID: 4275492
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.
    Marsden CD, Barry PE, Parkes JD, Zilkha KJ.
    J Neurol Neurosurg Psychiatry; 1973 Feb 01; 36(1):10-4. PubMed ID: 4691682
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid].
    Tohgi H, Ogawa M.
    No To Shinkei; 1977 Feb 01; 29(2):205-13. PubMed ID: 326277
    [No Abstract] [Full Text] [Related]

  • 9. [Comparison between results achieved by administering L-dopa and Sinemet in parkinsonism in the light of our records].
    Szulc-Kuberska J, Niewodniczy A, Poźniak-Patewics E, Wolczyk-Orzechowska M.
    Neurol Neurochir Pol; 1975 Feb 01; 9(5):611-5. PubMed ID: 1186952
    [Abstract] [Full Text] [Related]

  • 10. MK 486 and levodopa in treatment of Parkinsonism.
    Lieberman AN, Derby BM, Feigenson J, Goodgold A, Nesbitte J, Resurreccion EC, Valdivia F.
    Dis Nerv Syst; 1973 Feb 01; 34(4):167-71. PubMed ID: 4711885
    [No Abstract] [Full Text] [Related]

  • 11. A double-blind controlled study of MK-486 in Parkinson's disease.
    Schwartz AM, Olanow CW, Spencer A.
    Trans Am Neurol Assoc; 1973 Feb 01; 98():301-3. PubMed ID: 4594189
    [No Abstract] [Full Text] [Related]

  • 12. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W, Eisenlohr JJ.
    Nervenarzt; 1974 Jan 01; 45(2):22-9. PubMed ID: 4601993
    [No Abstract] [Full Text] [Related]

  • 13. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H.
    Trans Am Neurol Assoc; 1973 Jan 01; 98():241-5. PubMed ID: 4784941
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. L-dopa therapy combined with peripheral decarboxylase inhibitor (MK-486) in Parkinsonism.
    Ohmoto T, Kishikawa H.
    Folia Psychiatr Neurol Jpn; 1975 Jan 01; 29(1):1-12. PubMed ID: 1158313
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bensarazid with L-dopa in the treatment of parkinson's disease.
    Van Wieringen A.
    S Afr Med J; 1974 Feb 09; 48(6):206-9. PubMed ID: 4814495
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.